This editorial refers to 'Temporal course of vascular healing and neoatherosclerosis after implantation of durable-or biodegradable-polymer drug-eluting stents' † , by G. Guagliumi et al., on page 2448.
The evolution of coronary stenting from bare metal to first-and second-generation drug-eluting stents (DES) has been accompanied by a progressive reduction in major adverse cardiovascular events (MACE) including stent thrombosis, with the greatest differential between these devices occurring during the first year after deployment.
1 Beyond 1 year, clinical events (MACE, target lesion, or vessel failure) occur at a consistent 2-4%/year rate regardless of device.
2,3
The pathogenesis of very late events may relate to the common presence of a metallic implant that distorts and constrains the vessel and/ or a permanent polymer that can serve as nidus for inflammation, delayed/incomplete healing, neoatherosclerosis (NA), or thrombosis.
In an attempt to mitigate the adverse effects of polymers and improve clinical outcomes, bioresorbable polymer DES (BPDES) have evolved. SYNERGY (Boston Scientific Corporation), the first BPDES to gain US Food and Drug Administration approval, incorporates multiple design elements specifically aimed towards rapid and complete stent healing and reduced thrombosis. [4] [5] [6] Studies in animal models and cell assays have demonstrated that stent strut thickness directly impacts the time course and extent of endothelial coverage. 7, 8 Similarly, polymer distribution (abluminal vs. conformal) and the time course of polymer resorption (3-4 months vs. >12 months vs. permanent) appear to influence stent strut coverage/healing as well as the function/maturation of endothelial cells. [9] [10] [11] In aggregate, these data suggest that thinner struts and abluminal-only polymer distribution that resorbs within 3-4 months provide more rapid and complete stent healing. The spatial resolution of intravascular imaging with optical coherence tomography (OCT) provides a unique clinical tool with which to assess in vivo coronary stent coverage/healing, the extent and consistency of neointimal hyperplasia, and the development of NA. 12 The TRANSFORM (TRiple Assessment of Neointima Stent FOrmation to Reabsorbable polyMer)-OCT trial analysed serial OCT examinations performed immediately after, and at 3 and 18 months post-stenting, in patients with either stable coronary disease or acute coronary syndromes who were randomly assigned to treatment with either the SYNERGY or the RESOLUTE (Medtronic, Inc.) coronary stents. 13 SYNERGY and RESOLUTE differ in strut thickness (74 vs. 89 lm, respectively), polymer composition (PLGA vs. tricomponent BioLinx), polymer distribution (abluminal vs. conformal), time course for polymer resorption (3-4 months vs. permanent), metal alloy frame [PtCr vs. CoNi (MP35N)], and the drug delivered (everolimus vs. zotarolimus). Despite these marked differences, OCT measures of stent coverage/healing at 3 and 18 months, and the development of NA at 18 months, were not statistically different between devices. As SYNERGY incorporates multiple design iterations to facilitate stent healing, has this objective failed? On closer examination, possibly not. First, the OCT co-primary endpoint of maximum length of uncovered stent struts (length endpoint) at 3 months was chosen to reflect the rate/extent of early stent healing.
As strut thickness and the adequacy of strut embedment are directly related to strut coverage, high stent deployment pressures (> _ 20 atm) used for both devices optimized strut embedment and minimized malposition. Although the length endpoint was similar at 3 months (when polymer is present on both devices), by 18 months (beyond PLGA resorption) a difference becomes apparent (mean ± SD 1.5 mm ± 2.0 mm SYNERGY vs. 2.6 mm ± 3.1 mm RESOLUTE; P = 0.04). Further, variability in the length endpoint following RESOLUTE is greater despite a higher number of struts analysed. Interestingly, comparison of these same stents in a porcine coronary model demonstrated similar degrees of moderate/severe and severe inflammation at 90 days (polymer remains present for both), but a reduction in severe inflammation at 180 days (after PLGA resorption) following SYNERGY. 10 Thus, choice of the 3-month time point when polymer is present on both devices could miss potential benefits accrued by polymer resorption after SYNERGY. Second, the coprimary endpoint per cent of patients with frames of in-stent NA (NA endpoint) at 18 months was not statistically different between stents. Importantly, estimates used to power this endpoint were derived from histopathological studies and grossly overestimated the observed rates, making the analysis underpowered and the comparison between stents inconclusive. Indeed, the observed per cent of patients with OCT frames showing in-stent NA was numerically greater (by 37%) following RESOLUTE (15.9% vs. 11.6% SYNERGY) and 'real' differences between devices may have been missed. Finally, 18 months is early for NA assessment and a later time point may have captured a greater portion of patients. Although limitations in study design make conclusions regarding differences (or lack thereof) between stents difficult, valuable insights are gleaned. Marked reductions in the per cent of uncovered struts were observed for both devices between 3 and 18 months. Despite the high-pressure stent deployment technique employed, the per cent of covered struts at 3 months by OCT in TRANSFORM (73%) is the lowest yet reported (Take home figure) , and could also have been influenced by target lesion and patient variables. The per cent of initially malposed struts was significantly reduced from 3 to 18 months due to neointimal tissue ingrowth for both devices. Finally, the % frames with low signal pattern neointima (consistent with lipid, fibrin, or inflammation) was reduced to a similar degree following both stents and could be explained by protocol-driven high-intensity statin therapy, with similar low levels of LDL achieved. This important observation supports aggressive lipid-lowering therapies to optimize late clinical outcomes after coronary stenting. The authors should be congratulated on a well-designed and executed clinical trial that provides new in vivo insights into contemporary stent healing and the development of NA. Their work demonstrates that contemporary second-and third-generation DES are associated with rapid healing and low frequency of NA to 18 months regardless of polymer distribution, durability, or specific drug delivered. Differences between devices in OCT measures of healing and NA appear subtle, and demonstration of meaningful differences in clinical outcomes awaits longer-term follow-up from ongoing randomized trials.
